TAZORAC — Class II drug recall D-0099-2017
Terminated recall by Allergan Sales, LLC, reported 2016-10-19, distributed nationwide. Failed Content Uniformity Specifications
| Recall number | D-0099-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Allergan Sales, LLC, Waco, TX, United States |
| Recall initiated | 2016-06-30 |
| Classified | 2016-10-13 |
| Reported by FDA | 2016-10-19 |
| Terminated | 2017-12-06 |
| Distributed | Nationwide (US) |
| UPC / GTIN / UDI-DI | 00300238335036, 00300238335104 |
| NDC | 00023-8335-03, 00023-8335-10 |
| Lot numbers | 05/17, 10/16, 82579, 85088 |
Product
TAZORAC (tazarotene) Gel 0.05%, Rx only, For Dermatologic Use Only, Not for Ophthalmic Use, packaged in a) 30 g tubes (NDC: 0023-8335-03, UPC: 300238335036) and b)100 g tubes,(NDC: 0023-8335-10, UPC: 300238335104), Manufactured by: Allergan Inc., Irvine, CA 92512.
Reason for recall
Failed Content Uniformity Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0099-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.